Last updated: September 7, 2026
Avelumab, marketed as Bavencio by Merck KGaA and Pfizer, is a commercial immuno-oncology asset with a concentrated market position. Its strongest franchise is first-line maintenance treatment for advanced urothelial carcinoma. Merkel cell carcinoma provides a smaller, clinically important niche. Revenue growth has been constrained by intense competition from pembrolizumab, nivolumab, atezolizumab, and durvalumab, along with the limited number of approved indications.
Merck KGaA and Pfizer have not disclosed a separate, fully consolidated global revenue series that is directly comparable across all years. Merck KGaA reports Bavencio sales in euros, while Pfizer reports alliance economics under its own accounting structure. Public filings indicate that Bavencio developed into a commercial product in the low hundreds of millions of euros annually rather than a multibillion-euro oncology franchise (Merck KGaA, 2024; Pfizer, 2024).
What is avelumab approved to treat?
Avelumab is a fully human IgG1 monoclonal antibody targeting programmed death ligand 1, or PD-L1. Unlike several competing checkpoint inhibitors, its IgG1 structure retains antibody-dependent cellular cytotoxicity activity, although the commercial effect of that mechanism has not produced a clear market advantage.
| Market |
Avelumab regulatory position |
| Merkel cell carcinoma |
FDA accelerated approval in 2017 for metastatic disease; later converted to regular approval |
| Urothelial carcinoma |
FDA accelerated approval in 2017 for locally advanced or metastatic disease after platinum chemotherapy |
| Urothelial carcinoma maintenance |
FDA approval in 2020 for first-line maintenance after platinum-based chemotherapy in patients without progression |
| Renal cell carcinoma |
Investigated in combination with axitinib, but not a durable approved commercial franchise |
| Non-small cell lung cancer and other tumors |
Clinical development did not establish a major approved market |
The maintenance indication is the central commercial asset. The JAVELIN Bladder 100 trial showed that maintenance avelumab plus best supportive care improved overall survival compared with best supportive care alone in patients whose disease had not progressed after platinum chemotherapy (Powles et al., 2020).
How has Bavencio revenue changed over time?
Bavencio revenue increased after the 2017 launches but remained below the scale achieved by leading PD-1 products. The commercial trajectory reflects three factors: expansion into first-line maintenance urothelial cancer, increased competition in checkpoint inhibition, and the small addressable population for Merkel cell carcinoma.
What do Merck KGaA and Pfizer report financially?
Merck KGaA identifies Bavencio as one of its key Healthcare products and reports product sales in its annual and quarterly filings. Pfizer reports its economic interest through the companies' strategic alliance and does not present the asset as a stand-alone, globally comparable revenue line in the same manner.
The public financial record supports the following trajectory:
| Period |
Commercial development |
Financial interpretation |
| 2017-2019 |
Initial launches in Merkel cell carcinoma and urothelial carcinoma |
Early commercialization and limited patient population |
| 2020-2021 |
First-line maintenance approval in urothelial carcinoma |
Main expansion phase and strongest growth catalyst |
| 2022-2023 |
Mature maintenance market |
Continued sales, but slower growth as competing checkpoint therapies expanded |
| 2024 onward |
Mature, competitive product |
Greater emphasis on retention, geographic penetration, and lifecycle management |
Merck KGaA's reporting indicates that Bavencio achieved annual sales in the low hundreds of millions of euros by the early 2020s. That scale is meaningful within a specialty oncology portfolio but modest compared with Keytruda, Opdivo, Imfinzi, and Tecentriq. The product therefore contributes to oncology revenue without materially changing the overall financial profile of either alliance partner (Merck KGaA, 2023, 2024; Pfizer, 2023, 2024).
What are the main market drivers for avelumab?
The largest demand driver is the use of avelumab as maintenance therapy after platinum-based chemotherapy in advanced urothelial carcinoma.
Urothelial carcinoma maintenance
The maintenance model gives Bavencio a defined treatment position:
- Patients receive platinum-based chemotherapy.
- Patients without disease progression receive avelumab maintenance.
- Treatment continues until disease progression or unacceptable toxicity.
This sequence allows avelumab to capture patients across multiple chemotherapy regimens and creates a recurring-treatment model. The indication is less dependent on biomarker selection than some competing immunotherapy uses, which supports treatment adoption.
The limitation is that many patients with advanced urothelial cancer now receive immune checkpoint therapy earlier in the treatment pathway. Increased use of pembrolizumab-containing regimens and evolving antibody-drug conjugate combinations can reduce the number of patients eligible for post-chemotherapy avelumab maintenance.
Merkel cell carcinoma
Merkel cell carcinoma is a high-value but small market. Avelumab has durable clinical relevance in this setting, especially for metastatic disease, but the incidence is too low to support blockbuster economics. Competing products, including pembrolizumab and retifanlimab, further restrict growth.
Geographic expansion
The United States, Europe, Japan, and other developed oncology markets are the principal commercial regions. Market access depends on national reimbursement decisions, treatment guidelines, biomarker practices, and the availability of alternative PD-1 or PD-L1 antibodies.
Avelumab has less global commercial leverage than pembrolizumab because its approved indication set is narrower and its brand position is more dependent on a single urothelial carcinoma treatment sequence.
How does avelumab compare with competing checkpoint inhibitors?
Avelumab competes in a crowded class where prescribing decisions are often driven by indication, trial evidence, reimbursement, dosing convenience, and institutional protocols.
| Drug |
Principal commercial strengths |
Competitive effect on avelumab |
| Pembrolizumab |
Broad indication base, strong brand, extensive clinical development |
Most significant broad-market competitor |
| Nivolumab |
Broad oncology presence and combination experience |
Competes across urothelial and other tumor types |
| Atezolizumab |
PD-L1 mechanism and established urothelial cancer presence |
Direct class competition, although market position has changed by indication |
| Durvalumab |
Strong lung cancer franchise and expanding oncology use |
Competes for institutional immunotherapy budgets |
| Retifanlimab |
Activity in Merkel cell carcinoma |
Narrows avelumab's rare-cancer differentiation |
| Avelumab |
First-line urothelial carcinoma maintenance and Merkel cell carcinoma |
Strongest where maintenance sequencing is specified |
Avelumab's commercial weakness is not a lack of clinical utility. It is the relative breadth of competing products. Pembrolizumab and nivolumab can be selected across many tumor types, allowing hospitals and oncology practices to consolidate purchasing and physician experience around a small number of brands.
What is the FDA regulatory status of Bavencio?
Bavencio is approved under a biologics license application rather than a conventional small-molecule new drug application. Its key FDA milestones are:
| Date |
FDA event |
| March 2017 |
Accelerated approval for metastatic Merkel cell carcinoma |
| May 2017 |
Accelerated approval for locally advanced or metastatic urothelial carcinoma after platinum chemotherapy |
| June 2020 |
Approval for first-line maintenance therapy in advanced urothelial carcinoma |
| Subsequent years |
Confirmatory and lifecycle developments refined its commercial positioning |
The urothelial carcinoma maintenance indication became the principal regulatory foundation for the product. Avelumab's broader clinical development program did not produce the same level of commercial expansion as the development programs for pembrolizumab, nivolumab, or durvalumab (FDA, 2024).
What patents protect avelumab?
Avelumab is a biologic, so its exclusivity analysis differs from that of a small-molecule drug.
Orange Book status
The FDA Orange Book primarily lists patents associated with approved drug products submitted under an NDA. Avelumab was approved under a BLA. As a result, the Orange Book is not the primary public source for its patent estate.
The relevant U.S. framework is the biologics patent system under the Biologics Price Competition and Innovation Act, including the Purple Book and the statutory patent-exchange process for biosimilar applicants. Patent protection may include:
- Antibody composition claims
- Binding-site or epitope claims
- Cell-line and expression claims
- Manufacturing-process claims
- Formulation claims
- Container and delivery-device claims
- Method-of-treatment claims
Avelumab's effective exclusivity cannot be reduced to one universal expiry date. The analysis depends on the patent family, terminal disclaimers, patent-term adjustment, patent-term extension, claim scope, and whether a biosimilar sponsor pursues litigation or a negotiated launch.
When does avelumab lose exclusivity?
The statutory 12-year U.S. reference-product exclusivity period for a biologic runs from first licensure, subject to statutory rules and product-specific interpretation. Avelumab was first licensed in the United States in 2017. That places the earliest U.S. biosimilar approval window around 2029, before considering patent disputes, settlements, or commercial launch timing (FDA, 2024).
Patent expiry may occur before or after the statutory biologic exclusivity date. A biosimilar applicant could challenge relevant patents before the statutory period ends, but approval and commercial launch remain separate events.
Are there biosimilar and generic entry risks for avelumab?
There is no conventional generic pathway for avelumab. The relevant competitive threat is a biosimilar approved under section 351(k) of the Public Health Service Act.
Biosimilar risk
Avelumab is exposed to eventual biosimilar competition because:
- It is a commercially established monoclonal antibody.
- Its clinical mechanism is well characterized.
- Its administration is suitable for hospital and infusion-center use.
- Its market has a defined maintenance indication.
- Its annual revenue provides a potential commercial base for biosimilar developers.
The practical risk is likely to emerge gradually. Biosimilar developers must establish analytical similarity, demonstrate sufficient clinical comparability, navigate interchangeability requirements where relevant, and secure payer and provider adoption. Avelumab's smaller revenue base may reduce the number of biosimilar entrants compared with pembrolizumab or trastuzumab.
Which companies are challenging avelumab?
No major publicly disclosed U.S. biosimilar litigation campaign against avelumab had produced a confirmed market launch by the end of 2024. Publicly identified litigation and settlement activity around the product was materially less visible than the litigation surrounding major small-molecule blockbusters and larger biologic franchises.
The principal future challengers are likely to be established biosimilar manufacturers with oncology infusion portfolios, including large European, Indian, Korean, and Chinese developers. Commercial entry would depend on patent strategy, reference-product supply, manufacturing capacity, and payer contracting.
What licensing deal supports Bavencio?
Merck KGaA and Pfizer entered a strategic alliance in 2014 to develop and commercialize avelumab and other immuno-oncology programs. Public announcements described an upfront payment of approximately $850 million from Pfizer to Merck KGaA, with potential milestone payments of up to approximately $2 billion (Merck KGaA & Pfizer, 2014).
The alliance structure gives each company access to the other's development, regulatory, and commercial capabilities. It also divides economics and complicates direct comparison between reported Bavencio sales and each partner's recognized revenue.
The deal reduces the need for either company to fund the entire global commercial infrastructure alone. Its drawback is shared economics in a market where avelumab competes against internally controlled products with broader indication portfolios.
What patent litigation and settlement risks affect avelumab?
The principal legal risks are likely to arise from biosimilar patent litigation rather than traditional generic Paragraph IV litigation.
Paragraph IV challenges
Paragraph IV certifications apply to patents listed in the Orange Book for NDA products. Because avelumab is a BLA biologic, a biosimilar sponsor would generally use the BPCIA framework rather than file a conventional Paragraph IV certification against an Orange Book-listed patent.
Potential disputes may involve:
- Whether the reference product's antibody claims cover the biosimilar
- The scope of formulation and manufacturing claims
- Patent-term validity
- Obviousness and written-description challenges
- Infringement under the BPCIA patent-exchange process
- Launch timing under a negotiated settlement
No publicly confirmed avelumab biosimilar settlement had established a market-entry date through the end of 2024.
How strong is the avelumab patent estate?
Avelumab's patent estate is commercially meaningful but likely less durable than the product's clinical exclusivity because biologic patent families can be challenged claim by claim.
Strength factors include:
- Complex antibody manufacturing
- Multiple potential claim types
- Difficulty designing around a clinically active antibody without creating a different molecule
- Manufacturing and analytical barriers to biosimilar development
- The ability to pursue composition, formulation, and process patents
Weakness factors include:
- Mature public knowledge of PD-L1 biology
- Extensive prior art in checkpoint antibodies
- Potential limitations on broad functional antibody claims
- The ability of biosimilar developers to challenge individual patents
- A narrower commercial indication base than leading checkpoint inhibitors
The estate is best characterized as moderate-to-strong for near-term lifecycle protection, but not sufficient to eliminate long-term biosimilar risk.
What generic launch scenarios exist for avelumab?
Three scenarios are commercially relevant.
| Scenario |
Likely market effect |
| No biosimilar until after statutory exclusivity and patent resolution |
Gradual erosion, with continued brand use in Merkel cell carcinoma and maintenance therapy |
| One or two biosimilars enter after negotiated patent settlement |
Moderate price pressure and hospital formulary substitution |
| Multiple biosimilars enter after broad patent invalidation |
Faster net-price erosion and reduced alliance economics |
The most likely initial effect is price competition in institutional accounts rather than immediate displacement of all branded use. Infusion-center purchasing, payer mandates, and provider familiarity will determine the speed of substitution.
What is the revenue exposure for Merck KGaA and Pfizer?
Bavencio is strategically relevant but not financially transformational. The alliance provides recurring oncology revenue and commercial infrastructure, but the product is not comparable in scale with Keytruda, Opdivo, or the largest tumor-necrosis-factor and oncology biologics.
Revenue sensitivity is highest in:
- Urothelial carcinoma treatment sequencing
- Reimbursement for maintenance therapy
- Competition from broader checkpoint inhibitors
- Hospital net pricing
- Biosimilar timing
- New indication approvals
- Patient persistence on maintenance treatment
A decline in urothelial maintenance share would likely have a larger effect on Bavencio's trajectory than changes in the small Merkel cell carcinoma market.
Key Takeaways
- Avelumab's core commercial indication is first-line maintenance treatment for advanced urothelial carcinoma.
- Merkel cell carcinoma provides clinical differentiation but limited revenue scale.
- Bavencio is a low-hundreds-of-millions-euro annual product, not a multibillion-dollar checkpoint franchise.
- Pembrolizumab, nivolumab, atezolizumab, and durvalumab create substantial competitive pressure.
- Avelumab is protected through biologic exclusivity and patent families rather than a conventional Orange Book strategy.
- The earliest U.S. biosimilar approval window is broadly associated with the 2017 first licensure date, subject to patent and regulatory developments.
- No major publicly confirmed biosimilar launch or settlement had established a U.S. entry date through the end of 2024.
- The 2014 Pfizer-Merck KGaA alliance included an approximately $850 million upfront payment and potential milestone payments of approximately $2 billion.
- Future revenue depends primarily on retention of urothelial carcinoma maintenance share and the timing of biosimilar competition.
FAQs
Is avelumab the same as Bavencio?
Yes. Avelumab is the active pharmaceutical ingredient, and Bavencio is its commercial brand name.
Is avelumab a PD-1 or PD-L1 inhibitor?
Avelumab is a PD-L1 inhibitor. It binds PD-L1 and prevents interaction with PD-1 and B7.1 receptors.
Can avelumab be substituted with pembrolizumab?
Not automatically. The products have different labels, clinical evidence, dosing protocols, payer rules, and regulatory indications. Substitution depends on the treatment setting and local formulary policy.
Does avelumab have a small-molecule generic equivalent?
No. Avelumab is a monoclonal antibody. Future competitors would enter as biosimilars rather than conventional generics.
Why has avelumab not reached Keytruda-level sales?
Its indication base is narrower, its Merkel cell carcinoma market is small, and its principal urothelial carcinoma use competes with checkpoint inhibitors that have broader tumor coverage and stronger institutional adoption.
References
-
Food and Drug Administration. (2024). Bavencio (avelumab) prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
Merck KGaA. (2023). Annual report 2022. Darmstadt, Germany.
-
Merck KGaA. (2024). Annual report 2023. Darmstadt, Germany.
-
Merck KGaA, & Pfizer Inc. (2014, November 17). Merck KGaA and Pfizer enter strategic alliance to develop and commercialize immunotherapies.
-
Pfizer Inc. (2023). Annual report 2022. New York, NY.
-
Pfizer Inc. (2024). Annual report 2023. New York, NY.
-
Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., ... Grivas, P. (2020). Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. The New England Journal of Medicine, 383(13), 1218-1230.
